Literature DB >> 28057768

TERT biology and function in cancer: beyond immortalisation.

Ana Pestana1,2, João Vinagre1,2, Manuel Sobrinho-Simões1,2,3,4,5, Paula Soares6,2,3,5.   

Abstract

Evasion of replicative senescence and proliferation without restriction, sometimes designated as immortalisation, is one of the hallmarks of cancer that may be attained through reactivation of telomerase in somatic cells. In contrast to most normal cells in which there is lack of telomerase activity, upregulation of TERT transcription/activity is detected in 80-90% of malignant tumours. In several types of cancer, there is a relationship between the presence of TERT promoter mutations, TERT mRNA expression and clinicopathological features, but the biological bridge between the occurrence of TERT promoter mutations and the aggressive/invasive features displayed by the tumours remains unidentified. We and others have associated the presence of TERT promoter mutations with metastisation/survival in several types of cancer. In follicular cell-derived thyroid cancer, such mutations are associated with worse prognostic features (age of patients, tumour size and tumour stage) as well as with distant metastases, worse response to treatment and poorer survival. In this review, we analyse the data reported in several studies that imply TERT transcription reactivation/activity with cell proliferation, tumour invasion and metastisation. A particular attention is given to the putative connections between TERT transcriptional reactivation and signalling pathways frequently altered in cancer, such as c-MYC, NF-κB and B-Catenin.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  TERT; cancer; telomerase; thyroid

Mesh:

Substances:

Year:  2017        PMID: 28057768     DOI: 10.1530/JME-16-0195

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  26 in total

1.  TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.

Authors:  Gustavo C Penna; Ana Pestana; José Manuel Cameselle; Denise Momesso; Fernanda Accioly de Andrade; Ana Paula Aguiar Vidal; Mario Lucio Araujo Junior; Miguel Melo; Priscila Valverde Fernandes; Rossana Corbo; Mario Vaisman; Manuel Sobrinho-Simões; Paula Soares; Fernanda Vaisman
Journal:  Endocrine       Date:  2018-06-15       Impact factor: 3.633

2.  Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients.

Authors:  Marta Viana-Pereira; Daniel Antunes Moreno; Paulo Linhares; Júlia Amorim; Rui Nabiço; Sandra Costa; Rui Vaz; Rui Manuel Reis
Journal:  Mol Biol Rep       Date:  2019-11-12       Impact factor: 2.316

Review 3.  Molecular testing in the diagnosis of differentiated thyroid carcinomas.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Salvatore Ulisse; Enke Baldini; Riccardo Giannini; Paolo Miccoli; Alessandro Antonelli; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

4.  GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.

Authors:  Xiaotian Yuan; Ninni Mu; Na Wang; Klas Strååt; Anastasios Sofiadis; Yanxia Guo; Adam Stenman; Kailin Li; Guanghui Cheng; Lu Zhang; Feng Kong; Lars Ekblad; Johan Wennerberg; Inga-Lena Nilsson; C Christofer Juhlin; Catharina Larsson; Dawei Xu
Journal:  Oncogene       Date:  2018-09-04       Impact factor: 9.867

5.  Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Authors:  Valentina Maggisano; Marilena Celano; Saverio Massimo Lepore; Marialuisa Sponziello; Francesca Rosignolo; Valeria Pecce; Antonella Verrienti; Federica Baldan; Catia Mio; Lorenzo Allegri; Marianna Maranghi; Rosa Falcone; Giuseppe Damante; Diego Russo; Stefania Bulotta
Journal:  Endocrine       Date:  2019-01-19       Impact factor: 3.633

Review 6.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

7.  NHP2 downregulation counteracts hTR-mediated activation of the DNA damage response at ALT telomeres.

Authors:  Maya Raghunandan; Dan Geelen; Eva Majerova; Anabelle Decottignies
Journal:  EMBO J       Date:  2021-02-17       Impact factor: 11.598

8.  Chicken telomerase reverse transcriptase mediates LMH cell pyroptosis by regulating the nuclear factor-kappa B signaling pathway.

Authors:  Yong Xiang; Yun Yu; Qingbo Li; Jian Chen; Yu Li; Weisheng Cao
Journal:  Poult Sci       Date:  2022-03-08       Impact factor: 4.014

9.  Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid Production.

Authors:  Derek B Allison; Justin Rueckert; Virgilius Cornea; Cortney Y Lee; Julie Dueber; Therese Bocklage
Journal:  Endocr Pathol       Date:  2022-01-08       Impact factor: 4.056

10.  Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice.

Authors:  Jianjun Han; Weiya Z Wysham; Yan Zhong; Hui Guo; Lu Zhang; Kim M Malloy; Hallum K Dickens; Gene Huh; Douglas Lee; Liza Makowski; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.